Summary There is marked bone loss after spinal cord injury prospectively included. Serum OPG and RANKL levels, bone (SCI); however, its pathogenesis and clinical management re- turnover markers (PINP, bone ALP, CTX), and bone mineral main unclear. The increased circulating levels of receptor ac- density (BMD) were assessed at baseline, at 6 months of fol- tivator of nuclear factor kB ligand (RANKL) associated with low-up, prior to initiating denosumab, and 6 months after treat- bone loss shortly after SCI and the prevention of bone loss ment. The results were compared with a healthy control group. Results At baseline, SCI patients showed higher RANKL with denosumab treatment suggest a contributory role of RANKL in SCI-induced osteoporosis. levels vs. controls which were correlated with days-since-SCI Introduction Bone turnover and bone loss are markedly and total hip BMD loss at 6 months. OPG levels were similar to increased shortly after SCI. However, the pathogenesis controls at baseline. After denosumab treatment, OPG showed and clinical management of this process remain unclear, no changes, whereas RANKL levels became undetectable in especially the role of the osteoprotegerin (OPG)/RANKL 67% of patients. Patients with undetectable RANKL during system in this disorder. The aim of this study
Osteoporosis International – Springer Journals
Published: Jun 4, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera